DB02 - Low Testosterone in Obesity: Should We Treat or Not?

Sunday, June 14, 2026

10:30 AM - 12:00 PM CT

Location: Room W375C

Debate Moderator(s)

Stephen Hammes, PhD,MD

Chief, Div of Endo & Metabolism
University of Rochester
Rochester, NY, United States

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Stephen R. Hammes, PhD,MD: No financial relationships to disclose

David Handelsman, MBBS, PhD, FRACP, FAHMS: No financial relationships to disclose

As obesity-associated hypogonadism becomes increasingly common, clinicians face a growing dilemma: should low testosterone in men with obesity be treated directly, or viewed primarily as a reversible consequence of excess adiposity and metabolic dysfunction? This debate will examine the physiologic, metabolic, and clinical evidence surrounding testosterone therapy in obesity, addressing implications for cardiometabolic health, fertility, body composition, and long-term safety.

Presentations:

10:30 AM - 10:35 AM CT

Richard E. Weitzman Outstanding Early Career Investigator Award
Awardee: Katrin Svensson, Associate Professor – Stanford University
10:30 AM - 12:00 PM CT

Low Testosterone in Obesity: Should We Treat or Not?
Debate Speaker: David J. Handelsman, MBBS, PhD, FRACP, FAHMS – Anzac Research Institute
10:30 AM - 12:00 PM CT

Low Testosterone in Obesity: Should We Treat or Not?
Debate Speaker: Franck Mauvais-Jarvis, MD,PhD – Tulane University Health Sciences Center